The influence of risk factors in promoting thrombosis during childhood: The role of acquired factors

Pediatric Hematology and Oncology

Volumn 23, Issue 5, 2006, Pages 399-410

  Günes, Adalet ^a   Baytan, Birol ^a   Günay, Ünsal ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Acquired risk factors; Children; Genetic risk factors; Thrombosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; GENETICS; HEREDITY; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; NEWBORN; RISK FACTOR; THROMBOSIS;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFECTION; MALE; RISK FACTORS; THROMBOSIS; TURKEY;

EID: 33746836497     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010600646324     Document Type: Article

References (40)

1. De Mooerloose P, Reber G, Perrier A, et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. 2000;110:125-129.
2. Hagstrom JN, Walter J, Bluebond-Langner R, et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr. 1998;133:777-781.
3. Junker R, Novak-Göttle U. The prothrombin G20210A mutation: a common cause of thrombophilia? J Lab Med. 1998;22:472-482.
4. Ocal IT, Sadeghi A, Pres RD. Risk of venous thrombosis in carriers of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase. Mol Diagn. 1997;73:329-331.
5. Andrew M, David, M, Adams M, et al. Venous thromboembolic complications in children: first analyses of the Canadian registry of VTE. Blood. 1994;83:1251-1257.
6. Gürgey A, Mesci L, Renda Y, et al. Factor V Q 506 mutation in children with thrombosis. Am J Hematol. 1996;53:37-39.
7. Novak-Göttle U, Dübbers A, Kececioglu D, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: a prospective study. J Pediatr. 1997;131:608-612.
8. Bonduel M, Sciuccati G, Hepner M, et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol. 2003;73:81-86.
9. Gürgey A, Unal S, Okur H, et al. Prothrombin G20210A mutation in Turkish children with thrombosis and the frequency of prothrombin C20209T. Pediatr Hematol Oncol. 2005;22:309-314.
10. Dunn AS, Kaboli P, Halfdanarson T, et al. Do patients followed in anticoagulation clinics for antiphospholipid syndrome meet criteria for the disorder? Thromb Haemost. 2005;94:548-554.
11. Rask O, Berntorp E, Ljung R. Risk factors for venous thrombosis in Swedish children and adolescents. Acta Pediatr. 2005;94:717-722.
12. Heller C, Becker S, Scharrer I, et al. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr. 1999;158:S117-5121.
13. Junker R, Koch HG, Auberger K, et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol. 1999;19:2568-2572.
14. Günther G, Junker R, Strater R, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31:2437-2441.
15. Gürgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: influence of underlying or coexisting factors. J Pediatr Hematol Oncol. 2001;23:159-164.
16. Ören H, Devecioglu O, Ertem M, et al. Analysis of pediatric thrombotic patients in Turkey. Pediatr Hematol Oncol. 2004;21:573-583.
17. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763-766.
18. Uttenreuther-Fischer MM, Vetter B, Hellmann C, et al. Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Pediatr. 1997;156:277-281.
19. Oran O, Teksam O. Dünyada ve Türkiye'de cocuk sagligive olum nedenleri (Child health in the world and Turkey: the causes of death during childhood). Katki Pediatri Dergisi (In Turkish). 2003;25:27-36.
20. Smith OP. Infectious purpura fulminanas: diagnosis and treatment. Br J Haematol. 1999;104:202-207.
21. Kirchhofer D, Rieder MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood. 1997;89:1270-1280.
22. Gürgey A, Mesci L. The prevalence of factor V leiden (1691 G-A) mutation in Turkey. Turk J Pediatr. 1997;39:313-315.
23. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
24. Balta G, Gürgey A. Metylenetetrahydrofolate reduktase (MTHFR) 677 C-T mutation in Turkish patients with thrombosis. Turk J Pediatr. 1999;41:197-199.
25. Balasa V, Gruppo RA. The relationship of mutation in the MTHFR, prothrombin and Pal-1 genes to the plasma level of homocytein in children and adults. Thromb Haemost. 1999:81:739-744.
26. Brown K, Luddington R, Baglin T. Efffect of the MTHFR C677T variant on risk of venosus thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;103:42-44.
27. Lane DA, Manucci OM, Bauer KA, et al. Inherited thrombophilia: Part I. Thromb Haemost. 1996;76:651-662.
28. Frosst P, Bloom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
29. Nowak-Göttle U, Strater R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphism of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischaemic stroke in childhood. Blood. 1999;94:3678-3682.
30. Brown K, Luddington R, Baglin T. Effect of MTHFR C677T variant on risk of venous thromboembolism: interaction with factor V leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;103:42-44.
31. Almawi WY, Tamim H, Kreidy R, et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005;19:189-196.
32. Cattaneo M, Tsai M, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997;17:1662-1666.
33. Fujimura H, Kawasaki T, Sakata T, et al. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increase the risk for deep venous vein thrombosis in patients with predisposition of thrombophilia. Thromb Res. 2000;98:1-8.
34. Akar N, Akar E, Akçay R, Avcu F, Yalçin A, Cin S. Effect of methylenetetrahydrofolate reduktase 677 C-T on factor V 1691 mutation in Turkish deep vein thrombosis patients. Thromb Res. 2000;97:163-167.
35. Akar N, Akar E, Misirlioglu M, Avcu F, Yalçin A, Cin S. Search for genetic factors thrombosis in Turkish population. Thromb Res. 1998;79:79-82.
36. Young G, Manco-Jhonson M, Gill JC, et al. Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost. 2003;1:1-5.
37. von depka M, Nowak-Gottl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood. 2000;96:3364-3368.
38. Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr. 1999;158(Suppl 3):97-104.
39. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
40. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74:415-425.